Introduction
============

Colorectal cancer is one of the most common malignancies [@B1]. Approximately 15-25% of patients with colorectal cancer are initially diagnosed with synchronous metastases [@B2], [@B3]. When the primary tumor and the metastatic lesions are resectable, curative surgery can improve the outcome [@B4]. The benefit of palliative resection of the primary tumor in patients with unresectable metastases remains unclear. Accumulating evidence indicates that certain populations can benefit from palliative resection [@B5]-[@B7]. In our previous study, we found that palliative resection improved overall survival (OS) and progression-free survival (PFS) in certain patients [@B8].

In colon cancer without distant metastasis, the post-surgical status of lymph nodes (LN) is a critical prognostic indicator, according to the International Union Against Cancer tumor-node-metastasis (AJCC/UICC TNM) grading system. Several other relevant indices, such as the total LN yield (i.e., the total number of LNs; TLN), the number of negative LNs (NLN), and the metastatic LN ratio (LNR), significantly affect the prognosis of patients with non-stage V colon cancer[@B9] and other types of cancers such as breast cancer[@B10], lung cancer[@B11] and gastric cancer[@B12]. In patients with stage V colon cancer undergoing curative resection, an increased LNR was shown to be an independent predictor of decreased OS [@B13], [@B14]. In this study, we evaluated the significance of the metastatic LNR in patients with stage IV colon cancer who underwent curative or palliative resection of the primary tumor.

Materials and Methods
=====================

Patients and treatment
----------------------

We retrospectively analyzed the complete data of 424 patients who were initially diagnosed with stage IV colon cancer at the Sun Yat-Sen University Cancer Center from January 2003 to December 2014. Patients who met the following criteria were enrolled: 1) underwent curative or palliative primary tumor resection with regional LN yield; the surgeries were either elective or emergency surgeries; 2) comprehensive assessment and multidisciplinary review were performed before the operation; 3) available records of routine blood tests before any treatment; 4) available paraffin-embedded tissue blocks; and 5) available follow-up information. Curative resection was defined as the complete resection of a macroscopic tumor (R0 resection) with negative pathological margins and no evidence of metastases [@B13].

Patients with rectal cancers, multiple colon cancers, hereditary colorectal cancer, inflammatory bowel disease, and second primary tumors as well as those who underwent an enterostomy were excluded from the study.

Data collection
---------------

Data on patient demographics, tumor characteristics, laboratory test results, and intact therapeutic procedures were obtained from our electronic medical records. The histopathology of the primary tumor, LN metastatic status, and perineural or vascular invasion status were confirmed by the Department of Pathology. Survival data were collected by telephone interview or review of medical records. The last follow-up was performed on September 30, 2017.

The LNR is defined as the number of metastatic LNs divided by the total number of retrieved LNs. Due to the lack of a uniform cutoff value, the median value of the LNR is generally accepted as the critical value [@B15], [@B16]. In our data, a cutoff of 0.2 was used for the LNR. Similarly, the cutoff values for the TLN and NLN were 11 and 7 based on the median values, respectively. The upper normal values (5 ng/mL and 35 ng/mL) were used as the cutoff values for carcinoembryogenic antigen (CEA) and carbohydrate antigen 19-9 (CA199). OS was defined as the time from diagnosis to death for any reason or the last follow-up.

Statistical analysis
--------------------

The distributions of the patient characteristics were assessed by the Chi square test. OS was estimated by the Kaplan-Meier method, and survival differences were analyzed by the log-rank test. Multivariate analyses and a Cox proportional hazards model were used to determine the independent prognostic factors for OS. SPSS version 23.0 (Statistical Product and Service Solutions, Chicago, IL, USA) was used to perform all statistical analyses. A *P* value \<0.05 was considered significant.

Human Rights
------------

The protocol of our study was approved by the Ethics Committee of the Sun Yat-Sen University Cancer Center (GZR2015-034) and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. Written informed consent was gathered from each patient.

Results
=======

Patient characteristics
-----------------------

A total of 424 patients were enrolled in this retrospective study. Their baseline clinicopathologic features are shown in Table [1](#T1){ref-type="table"}. The median age at diagnosis was 58 years (range, 19-90 years), and 61.8% of the patients were men. Most patients (75.2%) had initial elevated CEA levels, and 46% had increased initial CA199 levels. The primary lesion of 174 patients (42.0%) located in the right colon. Only 17.5% of the patients had undergone treatment before the resection of the primary lesion, including chemotherapy (15.1%), concurrent chemoradiotherapy (1.4%), and a resection of (a) metastatic lesion(s) (0.2%). The liver was the most frequent organ for metastasis; other metastatic sites included the peritoneal and pelvic cavities, lungs, stomach, small intestine, ovaries, and LNs at multiple sites. A total of 81 (19.1%) and 153 (36.1%) patients presented with perineural and vascular invasion, respectively. The median count of the retrieved LNs was 11 (range, 0-58), and the median number of metastatic LNs was 2 (range, 0-29). The median LNR was 0.20 (range, 0-1).

The patients were divided into the curative (n = 71) and palliative (n = 353) resection groups. Table [1](#T1){ref-type="table"} shows a comparison of the patients\' characteristics between the two groups. Patients undergoing palliative resection had a higher initial CA199 level and a higher tumor depth than those undergoing palliative resection (*P* = 0.014 and*P* = 0.006, respectively); significantly more patients in the palliative resection group had multiple metastases than those in the curative resection group (*P* = 0.049). Last, a higher proportion of patients in the palliative resection group showed a TLN ≤11 when compared to those in the curative resection group (*P* = 0.001).

Survival analysis
-----------------

The associations between LN status, serum CA199 level, and OS are shown in Table [2](#T2){ref-type="table"}. Favorable prognostic factors in the total patient population included a higher TLN, more NLN, a low LNR, and a low CA199 level (Figure [1](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

Subgroup analyses by resection group are shown in Table [3](#T3){ref-type="table"}. The LNR was the only prognostic factor in the curative resection group. The median OS in patients undergoing curative resection with a low LNR was 74.33 months, it was 39.70 months in those with a high LNR (*P* = 0.001; Figure [2](#F2){ref-type="fig"}, Table [3](#T3){ref-type="table"}). High CA199 levels indicated a clear tendency of shorter OS (Figure [2](#F2){ref-type="fig"}, Table [3](#T3){ref-type="table"}). In the palliative resection subgroup, the prognostic values of TLN, NLN, LNR and CA199 were consistent with those of the total population (Figure [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

Univariate and multivariate Cox proportional hazards models were used to determine the independent prognostic factors for OS (Table [4](#T4){ref-type="table"}). Multivariate analysis identified the LNR (hazard ratio \[HR\] = 1.47, 95% confidence interval \[CI\] 1.14-1.91, *P* = 0.003 in all patients; HR = 1.43, 95% CI 1.09-1.86,*P* = 0.009 in the palliative resection subgroup) and the initial serum CA199 level (HR = 1.39, 95% CI 1.12-1.73,*P* = 0.003 in all patients; HR = 1.34, 95% CI 1.07-1.67,*P* = 0.01 in the palliative resection subgroup) as independent prognostic factors for OS.

Discussion
==========

In the present study, we found the LNR can be used as an independent prognostic factor in patients with stage IV colon cancer who underwent curative or palliative resection of the primary tumor. Considering the heterogeneity of colon cancer, it is easy to understand that patients with a lower CA199 level, fewer metastases at multiple sites, and a less advanced tumor infiltration status were more likely to have a longer OS. Surgical removal of the primary tumor has been reported to improve the outcomes of potentially curable patients with colorectal cancer [@B17], [@B18]. The benefit of palliative resection in patients with unresectable metastases remains controversial. With the development of systemic chemotherapy and the treatment of local lesions, the benefit of palliative resection of the primary tumor in specific patient populations has been gradually recognized [@B19], [@B20]. In our previous study, we found that patients with normal lactic dehydrogenase levels and a CEA level \<70 ng/mL could benefit from palliative operation surgery without serious surgery-related complications [@B8].

The prognostic factors of resectable metastatic colon cancer, such as the CEA level, tumor differentiation, and perineural invasion, have been extensively researched [@B17], [@B18], [@B21]. In this study, we found that the initial CA199 level was associated with OS in patients with resectable stage IV colon cancer. This is consistent with our identification of CA199 as an independent prognostic biomarker in patients with metastatic colorectal cancer [@B22].

The lymph nodes status is critical for prognosis in non-stage IV colon cancer in the current TNM staging system. Several studies have identified the LNR as a significant prognostic factor in patients with stage III colon cancer [@B23]-[@B25]; the LNR was a better prognostic factor that the positive LN count [@B16]. In stage IV colon cancer, researchers have suggested the prognostic significance of the LNR in patients with potentially curable disease [@B14], [@B26]-[@B28]. In patients with unresectable metastases, Ishihara et al. reported that negative LN dissection was associated with favorable outcomes [@B20]. Zhang et al reported more accuracy of survival prediction through the incorporation of negative LN into American Joint Committee on Cancer stages [@B29]. In our study, we further explored the role of the LNR in patients undergoing palliative resection. We identified the LNR as a in dependent negative predictor of prognosis in patients with metastatic colon cancer, specifically in those with unresectable metastases. A low LNR (high quota, rather than the number of retrieved LNs) could be interpreted as a strong anti-tumor immune response [@B30], [@B31].

The main limitations of this study are its retrospective study design and the relatively small number of patients with curative resection.

In conclusion, the LNR and initial CA199 levels were independently associated with OS in patients with metastatic colon cancer patients who underwent curative or palliative resection. Our data suggest that the LNR can serve as a prognostic indicator in patients with stage IV colon cancer and can be used to establish an adequate treatment strategy. Further validation studies are needed.

This study was supported by grants from the National Natural Science Foundation of China (81572409).

Note
====

Raw data was deposited in the Research Data Deposit system, <http://www.researchdata.org.cn>) of Sun Yat-Sen University Cancer and can be obtained from the corresponding authors on reasonable request.
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###### 

Clinical characteristics of the patients

  ------------------------------------------------------------------------------------------------------------------------------
                                                       Curative resection group (%)\   Palliative resection group (%)\   *P*
                                                       n = 71                          n = 353                           
  ---------------------------------------------------- ------------------------------- --------------------------------- -------
  Sex                                                                                                                    

  Male                                                 40 (56.3)                       222 (62.9)                        0.35

  Female                                               31 (43.7)                       131 (37.1)                        

  Age in years; median (range)                         58 (23-80)                      58 (19-90)                        0.99

  ≤60                                                  41 (57.7)                       204 (57.8)                        

  \>60                                                 30 (42.3)                       149 (42.2)                        

  Initial CEA (ng/mL)                                                                                                    0.36

  ≤5                                                   21 (29.6)                       80 (22.7)                         

  \>5                                                  49 (69)                         270 (76.5)                        

  Not available                                        1 (1.4)                         3 (0.8)                           

  Initial CA199 (ng/mL)                                                                                                  0.014

  ≤35                                                  48 (67.6)                       172 (48.7)                        

  \>35                                                 21 (29.6)                       174 (49.3)                        

  Not available                                        2 (2.8)                         7 (2.0)                           

  Primary tumor location                                                                                                 0.15

  Right colon                                          24 (33.8)                       154 (43.6)                        

  Left colon                                           47 (66.2)                       199 (56.4)                        

  Metastasis sites                                                                                                       0.002

  Liver                                                47 (66.2)                       149 (42.2)                        

  Lung                                                 4 (5.6)                         19 (5.4)                          

  Peritoneal and pelvic cavities                       10 (14.1)                       89 (25.2)                         

  Multiple organs                                      10 (14.1)                       96 (27.2)                         

  Therapy before the resection of the primary lesion                                                                     0.35

  None                                                 55 (77.5)                       295 (83.6)                        

  Chemotherapy                                         15 (21.1)                       49 (13.9)                         

  Concurrent chemoradiotherapy                         1 (1.4)                         5 (1.4)                           

  Resection of (a) metastatic lesion(s)                0                               4 (1.1)                           

  Pathological type                                                                                                      0.21

  Well differentiated                                  0                               0                                 

  Moderately differentiated                            55 (77.5)                       239 (67.7)                        

  Poorly differentiated                                14 (19.7)                       90 (25.5)                         

  Mucinous adenocarcinoma                              2 (2.8)                         24 (6.8)                          

  Tumor depth                                                                                                            0.049

  T1-2                                                 5 (7)                           8 (2.3)                           

  T3-4                                                 66 (93)                         345 (97.7)                        

  Lymph node metastasis                                                                                                  0.32

  N0                                                   27 (38)                         105 (29.7)                        

  N1                                                   27 (38)                         140 (39.7)                        

  N2                                                   17 (23.9)                       108 (30.6)                        

  TLN                                                                                                                    0.003

  ≤11                                                  27 (38.0)                       203 (57.5)                        

  Vascular invasion                                    29 (43.9)                       124 (43.1)                        0.90

  Perineural invasion                                  15 (22.7)                       66 (22.9)                         0.97
  ------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CA199, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; TLN, total lymph node yield.

###### 

Overall survival according to lymph node status and serum carbohydrate antigen 19 -9 levels in all patients

                    n (%)         Median OS, months (95% CI)   *P*
  ----------------- ------------- ---------------------------- ---------
  TLN ≤ 11          230 (54.25)   23.17 (19.70-26.64)          \<0.001
  \> 11             194 (45.75)   31.10 (24.97-37.23)          
  NLN ≤ 7           222 (52.36)   21.37 (18.26-24.47)          \<0.001
  \> 7              202 (47.64)   34.87 (29.16-40.58)          
  LNR^a^ ≤ 0.2      213 (50.24)   33.33 (29.61-37.06)          \<0.001
  \> 0.2            192 (45.28)   19.70 (17.00-22.39)          
  CA199^b^, ng/mL                                              \<0.001
  ≤ 35              220 (51.89)   30.40 (25.07-35.73)          
  \> 35             195 (45.99)   21.80 (17.89-25.71)          

^a^ Pathology confirmed the lack of lymph node tissue in 19 patients.

^b^ A total of 16 patients lacked information on initial serum CA 199 levels.

Abbreviations: CA199, carbohydrate antigen 19-9; CI confidence interval; LNR, metastatic lymph node ratio; NLN, negative lymph nodes; OS, overall survival; TLN, total lymph node yield.

###### 

Overall survival according to lymph node status and serum carbohydrate antigen 19-9 levels by type of resection

                  Curative resection group   Palliative resection group                         
  --------------- -------------------------- ---------------------------- --------------------- ---------
  TLN ≤ 11        Not reached                0.88                         20.10 (16.64-23.56)   0.001
  \> 11           Not reached                                             25.50 (22.11-28.89)   
  NLN ≤ 7         47.53 (30.24-64.83)        0.08                         20.07 (17.07-23.07)   \<0.001
  \> 7            74.33 (58.28-90.39)                                     26.00 (20.35-31.66)   
  LNR ≤ 0.2       74.33 (58.17-90.49)        0.01                         27.77 (24.04-31.49)   0.001
  \> 0.2          39.70 (20.17-59.24)                                     17.93 (15.86-20.00)   
  CA199 (ng/mL)                              0.09                                               0.01
  ≤ 35            Not reached                                             25.60 (23.16-28.04)   
  \> 35           47.53 (33.65-61.42)                                     20.07 (17.22-22.91)   

Abbreviations: CA199, carbohydrate antigen 19-9; CI confidence interval; LNR, metastatic lymph node ratio; NLN, negative lymph nodes; OS, overall survival; TLN, total lymph node yield.

###### 

Univariate and multivariate analyses of the factors affecting overall survival by Cox proportional hazard model

  Variable                  Overall population   Curative resection group   Palliative resection group                              
  ------------------------- -------------------- -------------------------- ---------------------------- ------- ------------------ ---------
  *Univariate analyses*                                                                                                             
  Initial CA199 \>35        1.43 (1.16-1.77)     0.001                      1.30 (0.06-2.83)             0.51    1.31 (1.05-1.63)   0.016
  TLN \<12                  0.65 (0.52-0.82)     \<0.001                    1.06 (0.48-2.34)             0.88    0.69 (0.54-0.87)   0.002
  NLN ≤7                    0.55 (0.44-0.68)     \<0.001                    0.51 (0.23-1.09)             0.82    0.65 (0.51-0.82)   \<0.001
  LNR ≤0.2                  1.72 (1.37-2.15)     \<0.001                    2.74 (1.27-5.93)             0.011   1.51 (1.19-1.92)   0.001
                                                                                                                                    
  *Multivariate analyses*                                                                                                           
  Initial CA199 \>35        1.39 (1.12-1.73)     0.003                      0.88 (0.43-2.08)             0.88    1.34 (1.07-1.67)   0.01
  TLN \<12                  0.83 (0.60-1.15)     0.27                       1.72 (0.59-4.97)             0.32    0.75 (0.53-1.06)   0.10
  NLN ≤7                    0.75 (0.52-1.06)     0.10                       0.63 (0.19-2.06)             0.44    0.91 (0.62-1.32)   0.61
  LNR ≤0.2                  1.47 (1.14-1.91)     0.003                      2.35 (0.93-5.96)             0.072   1.43 (1.09-1.86)   0.009

Abbreviations: CA199, carbohydrate antigen 19-9; CI confidence interval; LNR, metastatic lymph node ratio; NLN, negative lymph nodes; OS, overall survival; TLN, total lymph node yield.
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